Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4710 - Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective


10 Sep 2017


Poster display session


Urothelial Cancers


Alfonso Gomez de Liano Lista


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


A. Gomez de Liano Lista1, A. Necchi2, P. Lavaud3, J. Carles Galceran4, D. Castellano5, A. Ravaud6, I. Duran7, N. van Dijk8, P. Giannatempo2, Y. Loriot3, R. Morales Barrera9, G. De Velasco Oria De Rueda5, F. Lefort6, G. Martínez Bernal7, D. Raggi2, M. Gross-Goupil10, T. Powles1, M. Van der Heijden8

Author affiliations

  • 1 Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 2 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 5 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 6 Medical Oncology, Bordeaux University Hospital, 33000 - Bordeaux/FR
  • 7 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 8 Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 9 Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 10 Medical Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR


Abstract 4710


PD-1/PD-L1 inhibitors are changing the current landscape of mUC. Outcomes after discontinuation of ICI are unclear in this population.


Data from 8 European institutions was retrospectively collected. Target population was patients progressing on ICI. Univariate and multivariate analysis for overall survival (OS, calculated from the last date of ICI until death from any cause) as well as potential predictive factors of response to post-progression therapy (ppT) were performed. Tests were two-sided.


From March 2013 to April 2017, 291 patients were identified. 227 (78%) experienced progression (PD) on ICI. Median post-progression OS of ICI was 5 months (95% CI 3.7-6.3), being 8.6 (95%CI 7.5-9.7) if receiving ppT vs 1.8 (95%CI 1.5-2.1) if best supportive care alone (p 


Many patients do not receive subsequent chemotherapy, including CT-naive patients. Patients who receive post-ICI therapy have good outcomes. ICI does not appear to confer resistance to CT. Retrospective analysis is prone to bias.

Clinical trial identification

Legal entity responsible for the study

Alfonso Gómez de Liaño Lista




Y. Loriot: AstraZeneca, Roche, MSD, Pfizer, Astellas, Janssen, Clovis, Bristol-Myers Squib. T. Powles: Roche/Genentech, AstraZeneca, MSD. M. Van der Heijden: Roche/Genentech, AstraZeneca, Astellas, Bristol-Myers Squib, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.